drugset / Trial / NCT06019013
A Study of QLF3108 in Participants With Advanced Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of QLF3108 and will make a preliminary assessment of the anti-tumor activity of QLF3108 in patients with advanced solid tumor.
Timeline
- Start
- 2023-08-16
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QLF3108 | Unknown | — | — |
Indications
No indication recorded.